Avadel CNS v. Jazz Pharmaceuticals: Oxybate Patent Case Dismissed in 21 Days
Avadel CNS Pharmaceuticals filed suit against Jazz Pharmaceuticals in the Delaware District Court, asserting US12167991B2 against Jazz’s mixed-salt oxybate product XYWAV®. The case was voluntarily dismissed without prejudice under Rule 41(a)(1)(A)(i) just 21 days after filing — leaving the door open for future enforcement.
A rapid voluntary exit in a high-stakes oxybate patent battle
On 17 December 2024, Avadel CNS Pharmaceuticals, LLC — alongside co-plaintiff Flamel Ireland Limited — filed a patent infringement action against Jazz Pharmaceuticals, Inc. in the Delaware District Court before Judge Gregory B. Williams. The complaint asserted US12167991B2, a patent covering oxybate formulations, against Jazz’s XYWAV®, a mixed-salt oxybate product approved for idiopathic hypersomnia and narcolepsy symptoms. Avadel markets its own competing product, LUMRYZ®, an extended-release sodium oxybate treatment.
On 7 January 2025 — just 21 days after filing — Avadel and Flamel voluntarily dismissed all claims without prejudice pursuant to Rule 41(a)(1)(A)(i) of the Federal Rules of Civil Procedure. A dismissal without prejudice means the plaintiffs are not barred from reasserting the same claims in a future action. No merits ruling was issued, no defendant response had been filed, and the docket reflects no award of costs or attorneys’ fees.
The 21-day lifespan of this case is notably brief even for a voluntary dismissal, suggesting the action may have served a strategic purpose — such as preserving rights, testing a newly issued patent, or prompting licensing discussions — rather than proceeding toward trial. The specific commercial trigger for the rapid withdrawal is not disclosed in the public record. Given the competitive dynamics between LUMRYZ® and XYWAV® in the narcolepsy and hypersomnia market, the possibility of refiling or parallel proceedings cannot be excluded.
Filing to Dismissed without Prejudice in 21 days
Resolved in 21 days — well below the median district court patent case lifecycle of 2+ years
Dismissed without prejudice: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i): plaintiff’s right to exit before answer
Under Rule 41(a)(1)(A)(i), a plaintiff may voluntarily dismiss an action without a court order before the defendant serves an answer or a motion for summary judgment. This is the earliest and cleanest procedural exit. Because Jazz had not yet responded, Avadel exercised this right unilaterally. No judicial merits determination was made — the case simply never advanced beyond the complaint stage.
No merits ruling issuedWithout prejudice: Avadel retains the right to refile
A dismissal without prejudice does not extinguish the underlying claims. Avadel may reassert US12167991B2 against XYWAV® in a future action, subject to applicable statutes of limitations and any intervening legal developments. This contrasts with a dismissal with prejudice, which would bar the same claims permanently. The public record confirms the ‘without prejudice’ qualifier explicitly in both the notice of dismissal and the basis of termination.
Refiling remains possibleJazz exits without any adverse finding — for now
Jazz Pharmaceuticals was never required to file an answer, assert defenses, or challenge the validity of US12167991B2 in this proceeding. No injunctive relief, damages, or findings of infringement were entered. However, the dismissal without prejudice means Jazz cannot treat this as a resolved matter — the patent remains asserted against XYWAV® as a commercial risk, and future litigation remains a live possibility.
No adverse finding; risk persistsXYWAV® vs. LUMRYZ®: patent skirmish in a contested CNS market
The oxybate market — encompassing treatments for narcolepsy and idiopathic hypersomnia — is one of the most commercially significant and litigated spaces in CNS pharmaceuticals. Avadel’s LUMRYZ® competes directly with Jazz’s XYWAV® and Xyrem®. A swift dismissal without prejudice in a newly issued patent case suggests this action may be part of a broader IP strategy rather than an isolated filing. Stakeholders in the oxybate sector should monitor US12167991B2 closely for future enforcement activity.
Watch for refiling or licensing activityFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Avadel CNS Pharmaceuticals, LLC | Company | CNS pharmaceutical company — holder of US12167991B2, marketer of LUMRYZ® oxybate therapySearch in Eureka ↗ |
| Defendant | Jazz Pharmaceuticals, Inc. | Company | Jazz Pharmaceuticals, Inc. — developer and marketer of XYWAV®, a mixed-salt oxybate productSearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Avadel CNS Pharmaceuticals, LLCSearch in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice confirms all claims were withdrawn under Rule 41(a)(1)(A)(i), the provision permitting unilateral plaintiff exit before any defendant response. The ‘without prejudice’ qualifier is legally significant: it preserves Avadel’s right to refile identical claims against XYWAV®. No validity ruling, claim construction, or damages assessment was made. For Jazz, the absence of a merits ruling provides no estoppel protection — US12167991B2 remains live and enforceable against XYWAV® as of the case’s closure.
US12167991B2 — Extended-release oxybate formulation for CNS disorders
US12167991B2, filed under application number US18/758344, covers oxybate formulation technology relevant to the treatment of conditions including narcolepsy (cataplexy and excessive daytime sleepiness) and idiopathic hypersomnia. Oxybate — the sodium salt of gamma-hydroxybutyrate — is a controlled substance with a narrow but high-value therapeutic window. Patent protection in this space typically covers formulation-level innovations including release profiles, salt combinations, and dosing configurations rather than the active molecule itself.
The commercial stakes attached to US12167991B2 are substantial. Avadel’s LUMRYZ® and Jazz’s XYWAV® compete for the same patient population in a market where formulation patents can determine exclusivity timelines and reimbursement leverage. A patent covering distinct oxybate salt combinations — as XYWAV®’s calcium, magnesium, potassium, and sodium oxybate mixture suggests — may implicate claims about bioavailability, sodium load reduction, or release kinetics. Competitors and generic entrants in this space should assess their product formulations against this patent’s claims with particular care.
Should your oxybate product be screened against US12167991B2?
Any company developing or commercialising oxybate-based CNS formulations — including mixed-salt compositions, extended-release systems, or low-sodium oxybate variants — should treat US12167991B2 as a live enforcement risk. Avadel has demonstrated willingness to assert this patent in federal court, and the without-prejudice dismissal signals potential future action. R&D teams working on narcolepsy or hypersomnia therapeutics should review their formulation claims against this patent before advancing to IND or NDA stage.
PatSnap Eureka’s FTO Search Agent can map US12167991B2’s claim scope against your product formulation, identify related family members, and flag co-pending applications that may broaden the enforceable claim set. Eureka’s litigation monitoring layer will alert you to any new filings by Avadel CNS or Flamel Ireland Limited in this technology space, giving IP and regulatory teams the lead time needed to adapt formulation strategy or pursue design-arounds before a new suit is filed.
Run a freedom-to-operate analysis on US12167991B2 to assess your product’s exposure
Run FTO in Eureka →Similar oxybate and CNS formulation patent cases in Delaware federal court
Cases involving oxybate formulation patents and CNS pharmaceutical infringement actions filed in the Delaware District Court, including related Avadel-Jazz proceedings.
What this case signals for the CNS oxybate IP landscape
A 21-day voluntary dismissal on a freshly issued patent in a contested pharma market rarely signals the end of a dispute.
Newly issued patents are sometimes filed to establish priority or prompt settlement
US12167991B2 appears to have issued shortly before this action was filed. Litigants in pharmaceutical patent disputes occasionally file suit on newly issued patents to establish a litigation clock, test claim scope, or initiate licensing negotiations. The rapid withdrawal without prejudice is consistent with this pattern — though the actual trigger is not disclosed in the public record.
XYWAV® faces a persistent IP cloud until Avadel formally abandons the claim
For Jazz and XYWAV® commercial planners, a dismissal without prejudice is not a clearance. US12167991B2 remains a valid, enforceable patent. Until Avadel files with prejudice, licenses the patent, or the patent expires or is invalidated, XYWAV® should be treated as operating under ongoing infringement risk from this specific claim.
Avadel v Jazz — key questions answered
The case was voluntarily dismissed without prejudice on 7 January 2025, just 21 days after filing. Avadel and Flamel Ireland filed a Rule 41(a)(1)(A)(i) notice withdrawing all claims. No merits ruling was issued, and Avadel retains the right to refile against Jazz’s XYWAV® product under US12167991B2.
Avadel asserted US12167991B2 (application number US18/758344), a patent covering oxybate formulation technology. The case targeted Jazz’s XYWAV®, a mixed-salt oxybate product containing calcium, magnesium, potassium, and sodium oxybate, used for idiopathic hypersomnia and narcolepsy.
A dismissal without prejudice means no finding of infringement or validity was made, and Jazz faces no immediate legal liability. However, Avadel is not barred from refiling the same claims in the future. XYWAV® continues to operate under IP risk from US12167991B2 until the patent expires, is invalidated, or Avadel formally abandons its position.
The public record does not disclose the specific reason for the 21-day voluntary dismissal. Possible explanations include strategic refiling planning, ongoing licensing negotiations, or a decision to await further patent prosecution developments. The dismissal without prejudice preserves all of Avadel’s future enforcement options against XYWAV®.
The case involved Jazz’s XYWAV® — a mixed-salt oxybate combining calcium, magnesium, potassium, and sodium oxybate approved for idiopathic hypersomnia and narcolepsy — and Avadel’s LUMRYZ®, an extended-release sodium oxybate product for cataplexy and excessive daytime sleepiness in adults with narcolepsy. Both products compete in the CNS oxybate therapeutic market.
PatSnap Eureka searches patents and litigation data to answer instantly.